Gene Variant Detail

Transcript	gDNA	cDNA	Protein	Source Database	Genome Build
NM_004333.6	chr7:g.140753336A>T	c.1799T>A	p.V600E	RefSeq	GRCh38/hg38
NM_001354609.1	chr7:g.140753336A>T	c.1799T>A	p.V600E	RefSeq	GRCh38/hg38
NM_001354609.2	chr7:g.140753336A>T	c.1799T>A	p.V600E	RefSeq	GRCh38/hg38
NM_004333	chr7:g.140753336A>T	c.1799T>A	p.V600E	RefSeq	GRCh38/hg38
NM_001378474.1	chr7:g.140753336A>T	c.1799T>A	p.V600E	RefSeq	GRCh38/hg38
NM_001378468.1	chr7:g.140753336A>T	c.1799T>A	p.V600E	RefSeq	GRCh38/hg38
NM_004333.5	chr7:g.140753336A>T	c.1799T>A	p.V600E	RefSeq	GRCh38/hg38
XM_005250045	chr7:g.140753336A>T	c.1799T>A	p.V600E	RefSeq	GRCh38/hg38

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT01534897	Phase I	Dabrafenib	Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436	Completed	USA	0
NCT04151563	Phase Ib/II	Lucitanib + Nivolumab Docetaxel Cabozantinib + Nivolumab Cabozantinib + Ipilimumab + Nivolumab Docetaxel + Nivolumab Docetaxel + Nivolumab + Ramucirumab	A Phase 1/2 Study Evaluating Multiple Nivolumab Combination Therapy in Participants With Stage IV Non-small Cell Lung Cancer That Has Spread or Has Reoccurred After Failure of Chemotherapy and Immunotherapy	Withdrawn	USA \| ROU \| POL \| NOR \| NLD \| GRC \| DNK \| BEL \| ARG	1
NCT05694936	Phase II	Cetuximab + Panitumumab Cetuximab + Panitumumab + Valproic acid	Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer	Recruiting	AUS	0
NCT05270044	Phase III	Binimetinib + Encorafenib	Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. (COLUMBUS-AD)	Active, not recruiting	SWE \| ROU \| POL \| NOR \| NLD \| ITA \| HUN \| GRC \| GBR \| FRA \| ESP \| DEU \| CZE \| CHE \| CAN \| BRA \| BEL \| AUT \| AUS \| ARG	3
NCT03608046	Phase II	Avelumab + Cetuximab + Irinotecan	Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer (AVETUXIRI)	Unknown status	BEL	0
NCT03975231	Phase I	Dabrafenib + Trametinib	Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer	Recruiting	USA	0
NCT05788926	Phase I	TG6050	A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir)	Recruiting	FRA	0
NCT03864042	Phase I	Caffeine + Dextromethorphan + Losartan + Midazolam + Omeprazole Modafinil Bupropion + Rosuvastatin Binimetinib + Encorafenib	Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors	Completed	USA \| NLD \| ESP \| CAN \| BEL	0
NCT04557956	Phase Ib/II	Tazemetostat Dabrafenib + Tazemetostat + Trametinib	Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment	Recruiting	USA	0
NCT02130466	Phase Ib/II	Dabrafenib + Trametinib Pembrolizumab + Trametinib Dabrafenib + Pembrolizumab Dabrafenib + Pembrolizumab + Trametinib	A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)	Completed		0
NCT06640166	Phase II	Cetuximab + Encorafenib + Fluorouracil + Irinotecan + Leucovorin	Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab. (ECLYPse)	Recruiting	ITA	0
NCT06495125	Phase II	Defactinib + Nivolumab + RO5126766	Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer	Recruiting	USA	0
NCT04126733	Phase II	Nivolumab + Regorafenib	Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)	Completed	USA	0
NCT04576117	Phase III	Selumetinib Selumetinib + Vinblastine	A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma	Recruiting	USA \| CAN	0
NCT04862780	Phase Ib/II	BLU-945 BLU-945 + Osimertinib	(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC	Active, not recruiting	USA \| NLD \| GBR \| FRA \| ESP \| CAN	4
NCT04736173	Phase III	Zimberelimab Carboplatin + Paclitaxel + Pemetrexed Disodium AB154 + Zimberelimab Pembrolizumab	Study Comparing the Combination Domvanalimab and Zimberelimab With Pembrolizumab in Untreated Locally Advanced or Metastatic PD-L1-High Non-Small Cell Lung Cancer (ARC-10)	Active, not recruiting	USA \| TUR \| GRC	9
NCT04117945	Phase II	Regorafenib Irinotecan + Panitumumab Panitumumab Cetuximab + Irinotecan Cetuximab	Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer	Active, not recruiting	USA	0
NCT03839342	Phase II	Binimetinib + Encorafenib	Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations (BEAVER)	Active, not recruiting	CAN	0
NCT02178722	Phase Ib/II	Epacadostat + Pembrolizumab	Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers	Completed	USA	0
NCT03668431	Phase II	Dabrafenib + Spartalizumab + Trametinib	Dabrafenib + Trametinib + PDR001 In Colorectal Cancer	Unknown status	USA	0
NCT05005273	Phase II	Ipilimumab + Nivolumab BMS-986207 + Ipilimumab + Nivolumab	A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer	Completed	USA \| TUR \| POL \| ITA \| ISR \| FRA \| ESP \| DEU \| BEL \| AUS \| ARG	1
NCT02367859	Phase II	Dabrafenib + Trametinib	Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma	Completed	USA	0
NCT05954871	Phase I	Cetuximab + GDC-1971 GDC-1971 + Osimertinib	Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer	Active, not recruiting	USA \| CAN \| AUS	1
NCT01711632	Phase II	Vemurafenib	BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia	Completed	USA	0
NCT04585815	Phase Ib/II	Axitinib + PF-06801591 + SGN-TGT Binimetinib + Encorafenib + PF-06801591	Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)	Active, not recruiting	USA \| GBR \| BEL \| AUS	1
NCT04044430	Phase Ib/II	Binimetinib + Encorafenib + Nivolumab	Encorafenib, Binimetinib, and Nivolumab in Treating Patients With Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer	Terminated	USA	0
NCT04418167	Phase I	JSI-1187 Dabrafenib + JSI-1187	JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations	Suspended	USA	0
NCT04268550	Phase II	Selpercatinib	Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)	Active, not recruiting	USA	0
NCT02465060	Phase II	Nivolumab + Relatlimab Dabrafenib + Trametinib	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	Active, not recruiting	USA	2
NCT06007924	Phase II	Defactinib + RO5126766	A Study of Avutometinib and Defactinib in People With Thyroid Cancer	Recruiting	USA	0
NCT04074096	Phase II	Binimetinib + Encorafenib + Pembrolizumab	Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis (BEPCOME-MB)	Active, not recruiting	FRA	0
NCT01750918	Phase II	Fluorouracil Dabrafenib + Panitumumab Dabrafenib + Panitumumab + Trametinib Panitumumab + Trametinib	BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)	Completed	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| BEL	1
NCT05388123	Phase II	Rituximab + Vemurafenib	Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia	Recruiting	USA	0
NCT05364645	Phase II	Carboplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium + Selpercatinib	Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer	Withdrawn	USA	0
NCT02034110	Phase II	Dabrafenib + Trametinib	Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers	Completed	USA \| SWE \| NOR \| NLD \| ITA \| FRA \| ESP \| DNK \| DEU \| CAN \| BEL \| AUT	2
NCT05576896	Phase II	Encorafenib + Hydroxychloroquine + Panitumumab Cetuximab + Encorafenib + Hydroxychloroquine	Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory	Recruiting	USA	0
NCT02014909	Phase I	CDX-3379 CDX-3379 + Vemurafenib CDX-3379 + Trastuzumab CDX-3379 + Cetuximab CDX-3379 + Erlotinib	A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors	Completed	USA	0
NCT04310397	Phase II	Dabrafenib + Trametinib Dabrafenib + Spartalizumab + Trametinib	Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma	Terminated	USA	0
NCT06610682	Phase I	PLX8394	Feasibility of CSF and Plasma ctDNA in BRAF-altered Glioma During Treatment With Plixorafenib	Not yet recruiting	USA	0
NCT05777603	Phase I	Aztreonam + Pembrolizumab + Vancomycin	Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer	Recruiting	USA	0
NCT03244956	Phase II	Trametinib Dabrafenib + Trametinib	Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer (MERAIODE)	Unknown status	FRA	0
NCT06625775	Phase I	BBO-10203 + Trastuzumab BBO-10203	Dose Escalation and Expansion of BBO-10203 in Advanced Solid Tumors (BREAKER-101)	Recruiting	USA	0
NCT05854498	Phase II	Bevacizumab + Liposomal irinotecan + Trifluridine-tipiracil hydrochloride	Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer	Recruiting	USA	0
NCT04551521	Phase II	Atezolizumab Atezolizumab + Ipatasertib Atezolizumab + Pertuzumab + Trastuzumab Atezolizumab + Cobimetinib Alectinib Atezolizumab + Cobimetinib + Vemurafenib	CRAFT: The NCT-PMO-1602 Phase II Trial	Recruiting	DEU	0
NCT05676749	Phase I	Aldesleukin + C-TIL051 + Pembrolizumab	C-TIL051 in Non-Small Cell Lung Cancer	Recruiting	USA	0
NCT01638676	Phase Ib/II	Metformin + Vemurafenib	A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients	Recruiting	USA	0
NCT05957367	Phase Ib/II	DCC-3116 + Ripretinib Cetuximab + DCC-3116 + Encorafenib	A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies	Recruiting	USA	0
NCT06031688	Phase II	Tepotinib Ramucirumab + Tepotinib	Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)	Recruiting	USA	0
NCT01876641	Phase Ib/II	Decitabine + Vemurafenib	Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib	Terminated	USA	0
NCT04759846	Phase I	Binimetinib + Encorafenib	Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma	Withdrawn	ITA \| ESP \| CZE	0
NCT04166409	Phase III	Selumetinib Carboplatin + Vincristine Sulfate	A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma	Recruiting	USA \| CAN	1
NCT04201457	Phase Ib/II	Hydroxychloroquine + Trametinib Dabrafenib + Hydroxychloroquine + Trametinib	A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration	Recruiting	USA	0
NCT05039177	Phase Ib/II	Cetuximab + Encorafenib + ERAS-007 ERAS-007 + Palbociclib	A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies (HERKULES-3)	Active, not recruiting	USA	0
NCT03334617	Phase II	Danvatirsen + Durvalumab Durvalumab + Olaparib Cediranib + Durvalumab Durvalumab + Vistusertib Durvalumab + Trastuzumab deruxtecan Ceralasertib + Durvalumab	Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON)	Active, not recruiting	USA \| ISR \| FRA \| ESP \| DEU \| CAN \| AUT	1
NCT05064280	Phase II	Lenvatinib Pembrolizumab	Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases	Recruiting	USA	0
NCT04526782	Phase II	Docetaxel Binimetinib + Encorafenib	ENCOrafenib With Binimetinib in bRAF NSCLC (ENCO-BRAF)	Recruiting	FRA	0
NCT04034459	Phase II	Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Cetuximab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin	FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC (AIO-KRK-0116)	Active, not recruiting	DEU	0
NCT05469178	Phase Ib/II	Bemcentinib + Carboplatin + Pembrolizumab + Pemetrexed Disodium	A Study to Investigate the Safety, Tolerability, and Preliminary Anti-tumor Activity of Bemcentinib in Combination With Pembrolizumab Plus Pemetrexed and Carboplatin in Adult Participants With Untreated Non-squamous Non-small Cell Lung Cancer	Recruiting	USA	0
NCT05710406	Phase II	Cetuximab + Encorafenib	Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer	Recruiting	USA	0
NCT04581824	Phase II	Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Dostarlimab-gxly + Pemetrexed Disodium Carboplatin + Dostarlimab-gxly + Pemetrexed Disodium	Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)	Active, not recruiting	USA \| ROU \| POL \| ITA \| FRA \| ESP \| DEU \| BRA \| ARG	3
NCT06561386	Phase III	Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Nivolumab + Pemetrexed Disodium + Relatlimab Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Nivolumab + Pemetrexed Disodium + Relatlimab	A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 1-49% (RELATIVITY1093)	Recruiting	USA \| ROU \| POL \| NLD \| ITA \| IRL \| GBR \| FRA \| ESP \| DNK \| DEU \| CHE \| BRA \| BEL \| AUT \| AUS \| ARG	7
NCT01709292	Phase II	Vemurafenib	Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer	Active, not recruiting	USA	0
NCT05565417	Phase Ib/II	IMT-009	Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas	Recruiting	USA	0
NCT05926960	Phase II	Binimetinib + Encorafenib + Pembrolizumab Ipilimumab + Nivolumab	A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma (PORTSIDE)	Active, not recruiting	SVK \| POL \| ITA \| GBR \| ESP \| DEU \| CZE	0
NCT05525273	Phase II	Dabrafenib + Trametinib	Treatment of BRAF ( B-Rapidly Accelerated Fibrosarcoma) Mutated Papillary Craniopharyngioma (Swecranio)	Recruiting	SWE	0
NCT04061980	Phase II	Binimetinib + Encorafenib Binimetinib + Encorafenib + Nivolumab	Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer	Active, not recruiting	USA	0
NCT03732703	Phase Ib/II	Dexamethasone + Enasidenib + Ixazomib + Pomalidomide Cobimetinib + Dexamethasone + Ixazomib + Pomalidomide Dexamethasone + Erdafitinib + Ixazomib + Pomalidomide Dexamethasone + Ixazomib + Pomalidomide + Venetoclax Abemaciclib + Dexamethasone + Ixazomib + Pomalidomide Daratumumab + Dexamethasone + Ixazomib + Pomalidomide	Myeloma-Developing Regimens Using Genomics (MyDRUG) (MyDRUG)	Unknown status	USA	0
NCT06369259	Phase II	Cetuximab + Defactinib + RO5126766	Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer	Not yet recruiting	USA	0
NCT04390243	Phase II	Binimetinib + Encorafenib	Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation	Terminated	USA	0
NCT04657991	Phase III	Pembrolizumab Binimetinib + Encorafenib + Pembrolizumab	A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma	Active, not recruiting	USA \| TUR \| SVK \| POL \| NZL \| NOR \| ITA \| ISR \| HUN \| GRC \| GBR \| FRA \| FIN \| ESP \| DEU \| CZE \| CHE \| CAN \| BRA \| BGR \| BEL \| AUT \| ARG	4
NCT04534283	Phase II	Abemaciclib + LY3214996	A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.	Terminated	USA	0
NCT05453799	Phase II	XmAb20717	Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer	Unknown status	USA	0
NCT01721603	Phase II	Dabrafenib	A Phase 2 Prospective Trial of Dabrafenib With Stereotactic Radiosurgery in BRAFV600E Melanoma Brain Metastases	Terminated	USA	0
NCT06364917	Phase II	Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium Ipilimumab + Nivolumab Carboplatin + Ipilimumab + Nivolumab + Paclitaxel Carboplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab	DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC	Not yet recruiting	USA	0
NCT05153408	Phase Ib/II	BLU-701 BLU-701 + Osimertinib BLU-701 + Carboplatin + Pemetrexed Disodium	(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC	Terminated	USA	0
NCT02143050	Phase Ib/II	Dabrafenib + Metformin + Trametinib	Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients	Withdrawn	USA	0
NCT05308446	Phase II	Cetuximab + Encorafenib Cetuximab + Encorafenib + Nivolumab	Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation	Active, not recruiting	USA	1
NCT05026983	Phase II	Binimetinib + Encorafenib	Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases	Recruiting	USA	0
NCT05503797	Phase II	Cobicistat + PLX8394 PLX8394	A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations	Recruiting	USA \| SWE \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN	1
NCT05223673	Phase III	Trifluridine-tipiracil hydrochloride Futuximab + Modotuximab	Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer (COLSTAR)	Terminated	USA \| HUN \| FIN \| DNK \| BEL	1
NCT03803553	Phase III	Binimetinib + Cetuximab + Encorafenib Nivolumab Fluorouracil + Irinotecan + Leucovorin	Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer	Recruiting	USA	0
NCT05480306	Phase II	Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin DKN-01 + Fluorouracil + Irinotecan + Leucovorin Fluorouracil + Irinotecan + Leucovorin	Phase 2 Study of DKN-01 in Colorectal Cancer (DeFianCe)	Active, not recruiting	USA \| DEU	1
NCT04746924	Phase III	Tislelizumab BGBA1217 + Tislelizumab Pembrolizumab	A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer	Active, not recruiting	USA \| TUR \| POL \| NLD \| ITA \| FRA \| ESP \| DEU \| BRA \| AUS \| ARG	9
NCT03138889	Phase Ib/II	NKTR-214 + Pembrolizumab Carboplatin + Nab-paclitaxel + NKTR-214 + Pembrolizumab Carboplatin + NKTR-214 + Paclitaxel + Pembrolizumab Cisplatin + NKTR-214 + Pembrolizumab Carboplatin + NKTR-214 + Pembrolizumab + Pemetrexed Disodium	Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors	Terminated	USA \| FRA \| ESP \| DEU \| AUS	0
NCT02065063	Phase I	Palbociclib + Trametinib	A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors	Completed	USA	0
NCT06532032	Phase Ib/II	Amivantamab-vmjw + Docetaxel	A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer (swalloWTail)	Recruiting	USA \| TUR	1
NCT05203172	FDA approved	Encorafenib Binimetinib + Encorafenib Binimetinib + Encorafenib + Ribociclib Binimetinib + Cetuximab + Encorafenib Binimetinib	The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials	Recruiting	USA \| SVK \| NLD \| ITA \| ISR \| HUN \| GBR \| FRA \| ESP \| DEU \| CZE \| CAN \| BRA \| AUS	4
NCT06094296	Phase II	Cisplatin + Nivolumab + Pemetrexed Disodium BMS-986315 + Cisplatin + Nivolumab + Pemetrexed Disodium BMS-986315 + Carboplatin + Nivolumab + Pemetrexed Disodium BMS-986315 + Carboplatin + Nivolumab + Paclitaxel Carboplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Paclitaxel	A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)	Completed	USA \| AUS	0
NCT06102902	Phase I	Cetuximab + Encorafenib + ZEN-3694	Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer	Recruiting	USA	0
NCT02928224	Phase III	Cetuximab + Encorafenib Binimetinib + Cetuximab + Encorafenib Cetuximab + Irinotecan Cetuximab + Fluorouracil + Irinotecan + Leucovorin	Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer (BEACON CRC)	Completed	USA \| TUR \| POL \| NOR \| NLD \| ITA \| ISR \| HUN \| GBR \| FRA \| ESP \| DNK \| DEU \| CZE \| CAN \| BRA \| BEL \| AUT \| AUS \| ARG	7
NCT02693535	Phase II	Cobimetinib + Vemurafenib Atezolizumab + Talazoparib Regorafenib Larotrectinib Trastuzumab + Tucatinib Ipilimumab + Nivolumab Palbociclib Afatinib Entrectinib Talazoparib Pembrolizumab Temsirolimus Pertuzumab + Trastuzumab Atezolizumab + Pertuzumab/trastuzumab/hyaluronidase-zzxf Crizotinib Abemaciclib Sunitinib Olaparib	TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR)	Recruiting	USA	0
NCT03639714	Phase Ib/II	GRT-C901 + GRT-R902 + Ipilimumab + Nivolumab	A Study of a Personalized Neoantigen Cancer Vaccine	Completed	USA \| AUS	0
NCT05564403	Phase II	Fluorouracil + Leucovorin + Oxaliplatin Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin	Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)	Recruiting	USA	0
NCT01748149	Phase I	Vemurafenib	Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas	Active, not recruiting	USA \| CAN	0
NCT05241873	Phase Ib/II	BLU-451	(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations	Active, not recruiting	USA \| CAN	3
NCT05097378	Phase II	Binimetinib + Encorafenib	Perioperative Encobini in BRAFV600 Mutant Stage III (B/C/D) or Oligometastatic Stage IV Melanoma (PREMIUM)	Unknown status	GBR	0
NCT04995523	Phase Ib/II	AZD2936	A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC (ARTEMIDE-01)	Active, not recruiting	USA \| NLD \| FRA \| ESP \| DNK \| BRA \| BEL \| AUS	6
NCT02164916	Phase II	Cetuximab + Irinotecan Cetuximab + Irinotecan + Vemurafenib	S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer	Completed	USA	0
NCT05706779	Phase II	Cetuximab + Encorafenib	Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer (NEORAF)	Recruiting	FRA	0
NCT01740648	Phase I	Fluorouracil + Trametinib	Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer	Completed	USA	0
NCT03631706	Phase II	Bintrafusp alfa Pembrolizumab	M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)	Completed	USA \| TUR \| NLD \| ITA \| GRC \| FRA \| ESP \| DEU \| CAN \| BRA \| BEL \| ARG	6
NCT01336634	Phase II	Dabrafenib Dabrafenib + Trametinib	Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.	Completed	USA \| NOR \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU	3
NCT05435846	Phase I	Capmatinib + Trametinib	Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation	Terminated	USA	0
NCT01897116	Phase I	Hydroxychloroquine + Vemurafenib	A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma	Completed	USA	0
NCT05029882	Phase I	ABBV-400 + Bevacizumab ABBV-400 Bevacizumab + Trifluridine-tipiracil hydrochloride	Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab	Recruiting	USA \| POL \| ISR \| FRA \| ESP \| AUS	4
NCT06119581	Phase III	Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Cisplatin + LY3537982 + Pembrolizumab + Pemetrexed Disodium LY3537982 + Pembrolizumab Carboplatin + LY3537982 + Pembrolizumab + Pemetrexed Disodium	A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C (SUNRAY-01)	Recruiting	USA \| TUR \| SWE \| ROU \| POL \| NOR \| NLD \| ITA \| HUN \| GRC \| GBR \| FRA \| ESP \| DNK \| DEU \| CZE \| CHE \| CAN \| BRA \| BEL \| AUT \| AUS	7
NCT06578559	Phase II	Cetuximab + Encorafenib	Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC (BRICKET)	Recruiting	ITA	0
NCT06107413	Phase II	ABBV-400 + Bevacizumab + Fluorouracil + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin	Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab	Recruiting	USA \| ISR	3
NCT05650879	Phase I	ELVN-002 ELVN-002 + Trastuzumab deruxtecan Ado-trastuzumab emtansine + ELVN-002	ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer (HER2)	Recruiting	USA \| ITA \| FRA \| ESP \| AUS	2
NCT06440850	Phase II	Cobimetinib + Vemurafenib	Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation	Recruiting	USA	0
NCT05589818	Phase II	Pembrolizumab	Pembrolizumab for Advanced NSCLC and PS 2-3	Recruiting	USA	0
NCT05462613	Phase II	Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Aspirin + Bevacizumab + Capecitabine + Cyclophosphamide + Fluorouracil + Leucovorin + Oxaliplatin + Regorafenib Aspirin + Bevacizumab + Capecitabine + Cyclophosphamide + Fluorouracil + Irinotecan + Leucovorin + Regorafenib Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin	Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer (REPROGRAM-02)	Recruiting	FRA	0
NCT03365882	Phase II	Cetuximab + Irinotecan Pertuzumab + Trastuzumab	S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery	Active, not recruiting	USA	1
NCT05852223	Phase II	Pembrolizumab	Pembrolizumab in High-risk Thyroid Cancer (NePenThe)	Not yet recruiting	ITA	0
NCT04140500	Phase I	RO7247669	Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors	Active, not recruiting	TUR \| ISR \| GBR \| ESP \| DNK	5
NCT05330429	Phase II	Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Hu5F9-G4 + Irinotecan + Leucovorin	Study of Magrolimab Given Together With FOLFIRI/BEV in Patients With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) (ELEVATE CRC)	Terminated	USA \| ITA \| FRA \| ESP \| DEU \| CAN \| BEL \| AUS	2
NCT05182931	Phase II	Dabrafenib + Trametinib Trametinib	A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study) (I-FIRST)	Recruiting	AUS	0
NCT03708328	Phase I	RO7121661	A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors	Completed	USA \| NZL \| FRA \| ESP \| DNK	1
NCT06561360	Phase II	Cladribine + Rituximab Obinutuzumab + Vemurafenib	A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)	Recruiting	USA	0
NCT03475004	Phase II	Bevacizumab + Binimetinib + Pembrolizumab	Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer	Completed	USA	0
NCT02675946	Phase I	CGX1321 CGX1321 + Pembrolizumab Cetuximab + CGX1321 + Encorafenib	CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)	Unknown status	USA	1
NCT03235245	Phase II	Binimetinib + Encorafenib Ipilimumab + Nivolumab	Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib (EBIN)	Active, not recruiting	POL \| NLD \| ITA \| GBR \| FRA \| FIN \| ESP \| DNK \| DEU	0
NCT02915666	Phase I	Dabrafenib + Digoxin + Trametinib	A Clinical Trial of Patients With Melanoma	Withdrawn	USA	0
NCT06074588	Phase III	Docetaxel SKB264 Pemetrexed Disodium	Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)	Recruiting	USA \| TUR \| POL \| ITA \| ISR \| GRC \| GBR \| FRA \| ESP \| DEU \| CZE \| CAN \| BRA \| AUS	10
NCT03878719	Phase I	Binimetinib + Encorafenib	Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma	Terminated	ITA	0
NCT05059470	Phase II	Pembrolizumab	IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC	Recruiting	USA	0
NCT04619316	Phase II	Dabrafenib + Trametinib Trametinib	Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition (ERRITI)	Recruiting	DEU	0
NCT01659151	Phase II	Aldesleukin Fludarabine Vemurafenib	Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 Metastatic Melanoma	Active, not recruiting	USA	0
NCT04083976	Phase II	Erdafitinib	A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations (RAGNAR)	Active, not recruiting	USA \| POL \| ITA \| GBR \| FRA \| ESP \| DEU \| BRA \| BEL \| AUS \| ARG	4
NCT04238624	Phase II	Cemiplimab + Dabrafenib + Trametinib	Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer	Recruiting	USA	0
NCT03898908	Phase II	Binimetinib + Encorafenib	Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain (EBRAIN-MEL)	Active, not recruiting	ESP	0
NCT03189030	Phase I	pLADD	Study of Personalized Immunotherapy in Adults With Metastatic Colorectal Cancer	Terminated	USA	0
NCT03865082	Phase II	IMO-2125 + Ipilimumab + Nivolumab	Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)	Active, not recruiting	USA	0
NCT05510895	Phase II	Binimetinib + Cetuximab + Encorafenib	Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer (NeoBRAF)	Recruiting	DEU	0
NCT01754376	Phase II	Aldesleukin + Vemurafenib	Combined BRAF-Targeted Therapy and Immunotherapy for Melanoma	Terminated	USA	0
NCT06411600	Phase II	Bevacizumab + Cetuximab + Encorafenib Bevacizumab	Combination Therapy for BRAF-V600E Metastatic CRCm (BRAVE)	Recruiting	ESP	0
NCT03224767	Phase II	Cobimetinib + Vemurafenib	Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma	Active, not recruiting	USA	0
NCT01089101	Phase Ib/II	Selumetinib	Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma	Active, not recruiting	USA	0
NCT01726738	Phase II	Dabrafenib + Trametinib	LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations	Completed	USA	0
NCT03840915	Phase Ib/II	Bintrafusp alfa + Cisplatin + Pemetrexed Disodium Bintrafusp alfa + Docetaxel Bintrafusp alfa + Carboplatin + Pemetrexed Disodium Bintrafusp alfa + Cisplatin + Gemcitabine Bintrafusp alfa + Carboplatin + Gemcitabine Bintrafusp alfa + Carboplatin + Nab-paclitaxel	M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)	Completed	USA \| FRA \| BEL	0
NCT05141721	Phase II	Atezolizumab + GRT-C901 + GRT-R902 + Ipilimumab	A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer	Active, not recruiting	USA	0
NCT02257424	Phase Ib/II	Dabrafenib + Hydroxychloroquine + Trametinib	Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma (BAMM)	Completed	USA	0
NCT05554367	Phase II	Binimetinib + Palbociclib	Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial	Recruiting	USA	1
NCT03693170	Phase II	Binimetinib + Cetuximab + Encorafenib	Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer (ANCHOR-CRC)	Completed	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| BEL \| AUT	1
NCT04171622	Phase II	Lenvatinib + Pembrolizumab	Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer	Recruiting	USA	0
NCT04675710	Phase II	Dabrafenib + Pembrolizumab + Trametinib	Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer	Recruiting	USA	0
NCT03915951	Phase II	Binimetinib + Encorafenib	An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer	Active, not recruiting	USA \| NLD \| ITA \| ESP	1
NCT04800822	Phase I	PF-07284892 Cetuximab + Encorafenib + PF-07284892 Lorlatinib + PF-07284892 Binimetinib + PF-07284892	PF-07284892 in Participants With Advanced Solid Tumors	Terminated	USA	0
NCT02949843	Phase II	Nivolumab + Pembrolizumab	Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations	Terminated	USA	0
NCT04793815	FDA approved	Pembrolizumab	Lung Cancer Cryo-Activation as a Novel Approach to Augment Immunotherapy Efficacy (CRYOVATE)	Completed	CAN	0
NCT05217446	Phase II	Pembrolizumab Cetuximab + Encorafenib + Pembrolizumab	A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer (SEAMARK)	Active, not recruiting	USA \| SWE \| SVK \| POL \| NOR \| NLD \| ITA \| GBR \| FRA \| ESP \| DNK \| DEU \| CZE \| CAN \| BEL \| AUS	0
NCT04787341	Phase II	Regorafenib Panitumumab	PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence (PARERE)	Recruiting	ITA	0
NCT03255083	Phase I	DS-1205c + Osimertinib	DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer	Terminated		1
NCT04252339	Phase I	GDC-1971	RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors	Completed	USA	0
NCT01943422	Phase Ib/II	Interferon alpha-2b + Vemurafenib	Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma	Completed	USA	0
NCT03520686	Phase III	Carboplatin + Nogapendekin alfa inbakicept + Pembrolizumab + Pemetrexed Disodium Cisplatin + Nogapendekin alfa inbakicept + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Nogapendekin alfa inbakicept + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Nab-paclitaxel + Nogapendekin alfa inbakicept + Pembrolizumab	QUILT 2.023: A Study of N-803 in Combination With Current Standard of Care vs Standard of Care as First-Line Treatment for Patients With Stage 3 or 4 NSCLC.	Active, not recruiting	USA	0
NCT06194929	Phase Ib/II	Defactinib + Encorafenib + RO5126766 Defactinib + RO5126766	Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma (DETERMINE)	Recruiting	USA	0
NCT05985954	Phase I	Cetuximab + Encorafenib + Ulixertinib Cetuximab + Ulixertinib	Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy	Recruiting	USA	0
NCT03181100	Phase II	Atezolizumab + Cobimetinib Atezolizumab + Bevacizumab Atezolizumab + Nab-paclitaxel Atezolizumab + Cobimetinib + Vemurafenib Atezolizumab + Paclitaxel	Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer	Active, not recruiting	USA	0
NCT04623775	Phase II	Cisplatin + Nab-paclitaxel + Nivolumab + Pemetrexed Disodium Cisplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium Carboplatin + Nab-paclitaxel + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium Cisplatin + Nab-paclitaxel + Nivolumab + Pemetrexed Disodium + Relatlimab Cisplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium + Relatlimab Carboplatin + Nab-paclitaxel + Nivolumab + Pemetrexed Disodium + Relatlimab Carboplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium + Relatlimab	A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)	Active, not recruiting	USA \| ROU \| POL \| NLD \| ITA \| IRL \| GBR \| FRA \| ESP \| DEU \| CHE \| BRA \| BEL \| AUT \| AUS \| ARG	3
NCT03973918	Phase II	Binimetinib + Encorafenib	Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG (BRAF)	Terminated	USA	0
NCT05048797	Phase III	Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Trastuzumab deruxtecan	A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations	Recruiting	USA \| TUR \| POL \| NLD \| ITA \| FRA \| ESP \| DNK \| DEU \| CAN \| BRA \| BEL \| AUT	7
NCT04607421	Phase III	Bevacizumab + Capecitabine + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Cetuximab + Encorafenib Cetuximab + Encorafenib + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Cetuximab + Encorafenib + Fluorouracil + Irinotecan + Leucovorin	A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer	Active, not recruiting	USA \| SWE \| SVK \| POL \| NZL \| NOR \| NLD \| ITA \| GBR \| FIN \| ESP \| DNK \| DEU \| CZE \| CAN \| BRA \| BGR \| BEL \| AUS \| ARG	9
NCT05743036	Phase Ib/II	Cetuximab + Encorafenib + ZN-c3	ZN-c3 in Adult Participants With Metastatic Colorectal Cancer	Recruiting	USA \| POL \| ITA \| HUN \| ESP \| DEU \| AUS	0
NCT04017650	Phase Ib/II	Cetuximab + Encorafenib + Nivolumab	Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer	Active, not recruiting	USA	0

Gene	BRAF
Variant	V600E
Impact List	missense
Protein Effect	gain of function
Gene Variant Descriptions	BRAF V600E (previously reported as V599E) lies within the activation segment of the kinase domain of the Braf protein (PMID: 15035987). V600E confers a gain of function to the Braf protein as demonstrated by increased Braf kinase activity, downstream signaling, and the ability to transform cells in culture (PMID: 15035987, PMID: 29533785, PMID: 18697864).
Associated Drug Resistance
Category Variants Paths	BRAF mutant BRAF act mut BRAF V600E/K BRAF V600E BRAF mutant BRAF V600X BRAF V600E/K BRAF V600E

Gene Variant Detail

Contact

Filtering

Sorting

Filtering

Sorting